These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

599 related articles for article (PubMed ID: 33838758)

  • 1. The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
    Marson A; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton C; Hughes DA; Williamson P; Baker GA; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE;
    Lancet; 2021 Apr; 397(10282):1375-1386. PubMed ID: 33838758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.
    Marson AG; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton CO; Hughes DA; Williamson PR; Baker G; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE
    Health Technol Assess; 2021 Dec; 25(75):1-134. PubMed ID: 34931602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
    Marson A; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton C; Hughes DA; Williamson P; Baker GA; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE;
    Lancet; 2021 Apr; 397(10282):1363-1374. PubMed ID: 33838757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial.
    Marson AG; Al-Kharusi AM; Alwaidh M; Appleton R; Baker GA; Chadwick DW; Cramp C; Cockerell OC; Cooper PN; Doughty J; Eaton B; Gamble C; Goulding PJ; Howell SJ; Hughes A; Jackson M; Jacoby A; Kellett M; Lawson GR; Leach JP; Nicolaides P; Roberts R; Shackley P; Shen J; Smith DF; Smith PE; Smith CT; Vanoli A; Williamson PR;
    Lancet; 2007 Mar; 369(9566):1016-26. PubMed ID: 17382828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study protocol for a pragmatic randomised controlled trial comparing the effectiveness and cost-effectiveness of levetiracetam and zonisamide versus standard treatments for epilepsy: a comparison of standard and new antiepileptic drugs (SANAD-II).
    Balabanova S; Taylor C; Sills G; Burnside G; Plumpton C; Smith PEM; Appleton R; Leach JP; Johnson M; Baker G; Pirmohamed M; Hughes DA; Williamson PR; Tudur-Smith C; Marson AG
    BMJ Open; 2020 Aug; 10(8):e040635. PubMed ID: 32847927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levetiracetam as an alternative to phenytoin for second-line emergency treatment of children with convulsive status epilepticus: the EcLiPSE RCT.
    Appleton RE; Rainford NE; Gamble C; Messahel S; Humphreys A; Hickey H; Woolfall K; Roper L; Noblet J; Lee E; Potter S; Tate P; Al Najjar N; Iyer A; Evans V; Lyttle MD
    Health Technol Assess; 2020 Nov; 24(58):1-96. PubMed ID: 33190679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial.
    Marson AG; Appleton R; Baker GA; Chadwick DW; Doughty J; Eaton B; Gamble C; Jacoby A; Shackley P; Smith DF; Tudur-Smith C; Vanoli A; Williamson PR
    Health Technol Assess; 2007 Oct; 11(37):iii-iv, ix-x, 1-134. PubMed ID: 17903391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review.
    Nevitt SJ; Sudell M; Tudur Smith C; Marson AG
    Cochrane Database Syst Rev; 2019 Jun; 6(6):CD012065. PubMed ID: 31233229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial.
    Brown JE; Royle KL; Gregory W; Ralph C; Maraveyas A; Din O; Eisen T; Nathan P; Powles T; Griffiths R; Jones R; Vasudev N; Wheater M; Hamid A; Waddell T; McMenemin R; Patel P; Larkin J; Faust G; Martin A; Swain J; Bestall J; McCabe C; Meads D; Goh V; Min Wah T; Brown J; Hewison J; Selby P; Collinson F;
    Lancet Oncol; 2023 Mar; 24(3):213-227. PubMed ID: 36796394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial.
    Chamberlain JM; Kapur J; Shinnar S; Elm J; Holsti M; Babcock L; Rogers A; Barsan W; Cloyd J; Lowenstein D; Bleck TP; Conwit R; Meinzer C; Cock H; Fountain NB; Underwood E; Connor JT; Silbergleit R; ;
    Lancet; 2020 Apr; 395(10231):1217-1224. PubMed ID: 32203691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation.
    Wilby J; Kainth A; Hawkins N; Epstein D; McIntosh H; McDaid C; Mason A; Golder S; O'Meara S; Sculpher M; Drummond M; Forbes C
    Health Technol Assess; 2005 Apr; 9(15):1-157, iii-iv. PubMed ID: 15842952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy.
    Trinka E; Marson AG; Van Paesschen W; Kälviäinen R; Marovac J; Duncan B; Buyle S; Hallström Y; Hon P; Muscas GC; Newton M; Meencke HJ; Smith PE; Pohlmann-Eden B;
    J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1138-47. PubMed ID: 22933814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review.
    Nolan SJ; Marson AG; Weston J; Tudur Smith C
    Cochrane Database Syst Rev; 2015 Aug; (8):CD001911. PubMed ID: 26275105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review.
    Nolan SJ; Marson AG; Weston J; Tudur Smith C
    Cochrane Database Syst Rev; 2015 Jul; (7):CD001904. PubMed ID: 26204241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Person-centred experiential therapy versus cognitive behavioural therapy delivered in the English Improving Access to Psychological Therapies service for the treatment of moderate or severe depression (PRaCTICED): a pragmatic, randomised, non-inferiority trial.
    Barkham M; Saxon D; Hardy GE; Bradburn M; Galloway D; Wickramasekera N; Keetharuth AD; Bower P; King M; Elliott R; Gabriel L; Kellett S; Shaw S; Wilkinson T; Connell J; Harrison P; Ardern K; Bishop-Edwards L; Ashley K; Ohlsen S; Pilling S; Waller G; Brazier JE
    Lancet Psychiatry; 2021 Jun; 8(6):487-499. PubMed ID: 34000240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial.
    Baulac M; Rosenow F; Toledo M; Terada K; Li T; De Backer M; Werhahn KJ; Brock M
    Lancet Neurol; 2017 Jan; 16(1):43-54. PubMed ID: 27889312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial.
    Lyttle MD; Rainford NEA; Gamble C; Messahel S; Humphreys A; Hickey H; Woolfall K; Roper L; Noblet J; Lee ED; Potter S; Tate P; Iyer A; Evans V; Appleton RE;
    Lancet; 2019 May; 393(10186):2125-2134. PubMed ID: 31005385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical effectiveness of the psychological therapy Mental Health Intervention for Children with Epilepsy in addition to usual care compared with assessment-enhanced usual care alone: a multicentre, randomised controlled clinical trial in the UK.
    Bennett SD; Cross JH; Chowdhury K; Ford T; Heyman I; Coughtrey AE; Dalrymple E; Byford S; Chorpita B; Fonagy P; Moss-Morris R; Reilly C; Smith JA; Stephenson T; Varadkar S; Blackstone J; Quartly H; Hughes T; Lewins A; Moore E; Walji F; Welch A; Whelan E; Zacharia A; D'Oelsnitz A; Shah M; Xu L; Vezyroglou A; Mitchell K; Nizza IE; Ganguli P; Shafran R
    Lancet; 2024 Mar; 403(10433):1254-1266. PubMed ID: 38461840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenytoin versus valproate monotherapy for partial onset seizures and generalised onset tonic-clonic seizures.
    Nolan SJ; Marson AG; Pulman J; Tudur Smith C
    Cochrane Database Syst Rev; 2013 Aug; (8):CD001769. PubMed ID: 23970302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review.
    Nevitt SJ; Marson AG; Tudur Smith C
    Cochrane Database Syst Rev; 2019 Jul; 7(7):CD001911. PubMed ID: 31318037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.